ASH Teams Up With Leukemia & Lymphoma Society to Connect Patients to Clinical Trials
A collaboration between the American Society of Hematology (ASH) and The Leukemia & Lymphoma Society (LLS) will expand access to LLS’ Clinical Trial Support Center (CTSC), which provides clinical trials navigation and support to blood cancer patients and their families at no cost.
Starting in January 2020, ASH will give its 2,500 member clinicians in the U.S. and Canada access to the CTSC though a dedicated portal. Benefits include easy access to highly trained CTSC Nurse Navigators, who work one-on-one with patients and families to navigate trial inclusion and exclusion criteria and overcome potential barriers to enrollment. The portal enables the referring hematologist to provide key clinical details about their patients directly to LLS’ Nurse Navigators. This clinical information, in combination with other unique factors such as their overall health status, ability to travel for treatment, insurance restrictions, and available support systems, helps the Nurse Navigators optimally tailor their search for trials that are most appropriate to patients being referred.
“For many people diagnosed with a blood cancer, time is of the essence when trying to find an appropriate clinical trial,” said 2019 ASH President Roy Silverstein, MD, of the Medical College of Wisconsin in Milwaukee. “By partnering with LLS, our hope is to bring this wonderful service to more people while also decreasing the amount of time it takes to match to a trial by streamlining communication among the doctor, patient, and Nurse Navigator.”
This collaboration is being generously supported by Amgen Inc., a Champion Sponsor of the expansion of the CTSC. Other support comes from Seattle Genetics, Inc., Foundation Medicine Inc., Pharmacyclics & Janssen Biotech, and Genentech.
ASH member physicians can access the CTSC Nurse Navigators at www.hematology.org/clinicaltrialnavigation.
Blood’s Next Editor-in-Chief Takes the Helm
ASH is pleased to welcome Nancy Berliner, MD, the H. Franklin Bunn Professor of Medicine and Chief of Hematology at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, as the next editor-in-chief of the Blood journal, beginning in January 2020. The new deputy editor of Blood is Andrew W. Roberts, MBBS, of the Walter and Eliza Hall Institute of Medical Research in Victoria, Australia.
“Blood is an outstanding journal that celebrates the breadth of hematology and has the highest standards for peer review,” said Dr. Berliner. “I am deeply committed to the future of Blood and look forward to continuing to strengthen the journal as its editor-in-chief.”
Dr. Berliner’s vision for the future of Blood includes further expansion of the journal’s international and digital reach by continuing to increase the geographic diversity of the editorial board and creating dynamic content for online features.
Find the latest research in Blood at www.bloodjournal.org.
First Industry Datasets Submitted to ASH Research Collaborative Data Hub
The ASH Research Collaborative (ASH RC) has collaborated with two industry leaders, Novartis and Amgen, to include de-identified patient data from three separate studies of nearly 500 patients living with Sickle Cell Disease (SCD) and more than 1,000 patients with multiple myeloma, respectively, as part of an unprecedented data sharing initiative. Novartis and Amgen are the first two pharmaceutical companies to provide datasets to the growing collection of data in the ASH RC Data Hub, a platform designed to accelerate scientific discovery by gathering clinical data on rare blood diseases.
“The inclusion of the Novartis and Amgen data into the ASH RC Data Hub is incredibly exciting as it represents a new paradigm in how we can leverage disparate data sources to answer important clinical questions in a way that wasn’t possible before,” said Roy Silverstein, MD, of the Medical College of Wisconsin, who served as 2019 president of the ASH RC as well as 2019 ASH president.
“The data represent a key milestone for the ASH RC to harness the power of Big Data to aggregate and share data from people around the world all in one place. The ASH RC Data Hub will bridge the gap between academia and industry to accelerate the drug development pipeline and improve the treatment landscape for patients and families living with devastating blood diseases,” Dr. Silverstein said.
Since launching in 2018, the ASH RC Data Hub has captured data from more than 3,000 patients with SCD and 2,000 patients with myeloma. The ASH RC has also launched an SCD Clinical Trials Network that will use the Data Hub as the central data repository for trial sites. The ASH RC anticipates clinical trial data submissions to become an industry standard and is working closely with pharmaceutical companies and other data sources.